News | February 24, 2015

Lancaster General Health Receives First Commercial InCise Multileaf Collimator for CyberKnife M6 System

System delivers precise stereotactic body radiation therapy on a robotic platform

Accuray, CyberKnife M6, InCise, MLC, collimator, radiation therapy, SBRT

Image courtesy of Accuray inc.

February 24, 2015 — Accuray Inc. and Lancaster General Health announced that the first commercially available InCise multileaf collimator (MLC) for the CyberKnife M6 System has been received by Lancaster. The hospital selected the InCise MLC based on its ability to increase the system's treatment efficiency and extend its unique capabilities to a broader range of patient cases.

Evaluation of the InCise MLC with the CyberKnife M6 system has been successfully completed by two U.S. sites. Accuray conducted a rigorous evaluation of the device covering a wide range of functionality, performance, reliability and serviceability parameters. The collimator successfully met all predetermined criteria to the company's and the sites' full satisfaction.

The InCise MLC is the world’s first multileaf collimator to be available on a robotic platform. The system was designed to deliver extremely precise stereotactic body radiation therapy (SBRT). Using its robotic range of motion and continuous image guidance, the system follows the target throughout the treatment process, delivering individualized treatment with sub-millimeter precision. The CyberKnife M6 System can be used to treat tumors anywhere in the body, including the prostate, lung, brain, spine, liver, pancreas and kidney, and may offer hope to patients who have inoperable or surgically complex tumors, or who may prefer a clinically effective, non-surgical option.

"We look forward to treating our first patient using the newly configured CyberKnife M6 System. With the MLC we expect to reduce SBRT treatment times without sacrificing the precision we've come to expect from the system," said Jeffrey Eshleman, M.D., director of radiation oncology, Lancaster General Health. "In addition, the InCise MLC will expand patient access to SBRT to those people who previously may not have been eligible due to the size or type of their tumor. SBRT is typically a much shorter course of treatment than conventional radiation therapy. It has the potential to reduce the overall cost of patient care, and discomfort and scheduling inconvenience for the patient, versus conventional treatment."

For more information: www.accuray.com

Related Content

Top Score in Multiple Brain Metastases TROG 2018 Treatment Plan Study Achieved With Accuray Precision

Image courtesy of Accuray Inc.

News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
Mercy Signs Multi-System, Multi-Hospital Agreement for Accuray Radiotherapy Systems
News | Radiation Therapy | May 16, 2018
Accuray Inc. signed a multi-system, multi-hospital agreement with Mercy for the acquisition of Accuray Radixact and...
ViewRay Unveils New Soft Tissue Visualization Technologies for MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | April 30, 2018
ViewRay Inc. announced new magnetic resonance imaging (MRI) technologies under development for its MRIdian Linac...
MedStar Georgetown Conducts World's First Hyperscan Proton Therapy Treatment
News | Proton Therapy | April 27, 2018
For the first time, cancer patients in the Washington, D.C. metropolitan region have access to proton therapy, now...
Designed to support a broad range of planning and delivery technologies, SunCheck 2.0 streamlines and standardizes workflows, allowing greater overall focus on patient safety.
Technology | Quality Assurance (QA) | April 27, 2018
Sun Nuclear Corp. released significant new functionality for its SunCheck Platform for patient and machine quality...
RayStation Users Win Inaugural Treatment Planning World Championships
News | Treatment Planning | April 27, 2018
In the first World Championships of Treatment Planning, arranged by radiation oncology analytics company ProKnow and...
Brainlab Introduces New Hi-Res Planning Algorithm for VersaHD
News | Treatment Planning | April 24, 2018
Brainlab announced the implementation of a software solution that can achieve better radiation dose conformity around...
Shorter Radiotherapy Courses Safe and Effective for Prostate Cancer
News | Prostate Cancer | April 23, 2018
Radiotherapy given in high doses over a shorter period of time is safe and effective for prostate cancer patients,...
Elekta Expands Mosaiq Oncology Information System With PalabraApps
News | Oncology Information Management Systems (OIMS) | April 20, 2018
April 20, 2018 — Elekta announced that it is making a strategic investment in PalabraApps LLC to advance the developm
Overlay Init